8-K: NewAmsterdam Pharma Terminates $150 Million At-the-Market Offering

NewAmsterdam Pharma has suspended and terminated its $150 million at-the-market offering of ordinary shares, effective December 10, 2024.

Summary

• NewAmsterdam Pharma has terminated its at-the-market (ATM) offering, which was established on August 9, 2024.
• The offering allowed for the sale of up to $150 million of the company's ordinary shares.
• The termination was effective as of December 10, 2024.
• The company will not sell any further shares under the existing agreement unless a new prospectus or registration statement is filed.
• The underlying sales agreement with Cowen and TD Securities remains in effect, despite the termination of the ATM prospectus.

Sentiment

Score: 4

Explanation: The termination of a planned capital raise is generally viewed negatively by the market, suggesting a potential need for alternative financing and uncertainty about the company's financial position.

Negatives

• The termination of the ATM offering means the company will not be able to raise capital through this mechanism in the short term.

Risks

• The company may need to seek alternative financing methods if it requires additional capital.
• The termination of the ATM offering could be perceived negatively by investors.

Future Outlook

The company will need to file a new prospectus, prospectus supplement, or registration statement to sell shares under the sales agreement in the future.

Management Comments

• The company delivered written notice to Cowen and TD Securities that it was suspending and terminating the ATM prospectus.

Industry Context

At-the-market offerings are a common way for companies, particularly in the biotech sector, to raise capital. The termination of this offering suggests a change in the company's financing strategy or market conditions.

Comparison to Industry Standards

• Many biotech companies utilize ATM offerings to raise capital, often as a flexible alternative to traditional equity offerings.
• The termination of an ATM offering is not uncommon, and can be due to various factors such as market conditions, company-specific developments, or a change in financing strategy.
• Companies like Xencor and BioMarin have used ATM offerings in the past, and their performance after such offerings can be used as a benchmark for NewAmsterdam Pharma.

Stakeholder Impact

• Shareholders may react negatively to the termination of the ATM offering.
• The company may need to seek alternative financing methods, which could impact its financial flexibility.

Next Steps

• The company will need to file a new prospectus, prospectus supplement, or registration statement to sell shares under the sales agreement in the future.

Key Dates

Keywords

at-the-market offering, ATM, share offering, capital raise, prospectus, NewAmsterdam Pharma, Cowen, TD Securities